Human uraemic plasma stimulates release of leptin and uptake of tumour necrosis factor-α in visceral adipocytes

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3626-3631

  Aminzadeh, Mohammad A ^a   Pahl, Madeleine V ^a   Barton, Cyril H ^a   Doctor, Niraj S ^a   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adiponectin; Anorexia; Chronic kidney disease; Inflammation; Malnutrition

Indexed keywords

ADIPONECTIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; INTRAABDOMINAL FAT; KIDNEY FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; UREMIA;

ADIPOCYTES; ADULT; ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEPTIN; MALE; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; UREMIA;

EID: 71049172166     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp405     Document Type: Article

References (51)

1. Vaziri ND. Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 2004; 24: 469-473
2. Quiroz Y, Romero F, Ferrebuz A et al. Melatonin ameliorates oxida-tive stress, inflammation, proteinuria and progression in rats with renal mass reduction. Am J Physiol Renal Physiol 2008; 294: F336-F344
3. Bastard JP, Jardel C, Delattre J et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999; 99: 2221-2222
4. Kirchgessner TG, Uysal KT, Wiesbrock SM et al. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-2782
5. Sanchez-Margalet V, Martin-Romero C. Human leptin signaling in human peripheral blood mononuclear cells: activation of the JAK-STAT pathway. Cell Immunol 2001; 211: 30-36 (Pubitemid 32917755)
6. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
7. Roberts TK, Bailey JL. Beyond nutrition: neuropeptide signaling and muscle mass maintenance in chronic kidney disease. Kidney Int 2008; 74: 143-145
8. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83: 735-743
9. Mak RH, Cheung W, Cone R, Marks DL. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatr Nephrol 2005; 20: 427-431
10. Mak RH, Cheung W, Cone R et al. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794-797 (Pubitemid 43297887)
11. Mak RH, Cheung W, Cone R et al. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol 2006; 21: 1807-1814 (Pubitemid 44741157)
12. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
13. McCullough PA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-728
14. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
15. Excerpts from the United States Renal Data system 2005 Annual Data Report. Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47: S1-S286
16. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538
17. Koriakova NN, Rozhdestvenskaia ED, Kazantseva SV et al. Features of a cytokine profile in patients with chronic glomerulonephritis with progressive chronic renal failure. Te r A r k h 2006; 78: 14-17
18. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: Are there reasons to measure it? Blood Purif 2005; 23: 72-78
19. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
20. Yao Q, Axelsson J, Stenvinkel P et al. Chronic systemic inflammation in dialysis patients: an update on causes and consequences. ASAIO J 2004; 50: lii-lvii
21. Qureshi AR, Alvestrand A, Divino-Filho JC et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodial-ysis patients. J Am Soc Nephrol 2002; 1: S28-S36
22. Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911 (Pubitemid 29197978)
23. Bergstrom J. Inflammation, malnutrition, cardiovascular disease and mortality in end-stage renal disease. Po l A r c h M e d We w n 2000; 104: 641-643
24. Kaysen GA, Dubin JA, Muller HG et al. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61: 2240-2249
25. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998; 32: S118-S125
26. Trayhurn P, Wood IS. Signalling role of adipose tissue. Adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078-1081
27. Kaizu Y, Kimura M, Yoneyama T et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93-100
28. Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-668
29. Verma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740
30. Lee CT, Lee CH, Su Y et al. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004; 27: 835-841
31. Kagan A, Haran N, Leschinsky L et al. Leptin in CAPD patients: serum concentrations and peritoneal loss. Nephrol Dial Transplant 1999; 14: 400-405
32. Axelsson J, Heimburger O, Lindholm B et al. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005; 15: 131-136
33. Pecoits-Filho R, Nordfors L, Heimburger O et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002; 32: 811-817
34. Axelsson J, Qureshi AR, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229
35. Marchlewska A, Stenvinkel P, Lindholm B et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004; 66: 46-50
36. Martin-Romero C, Sanchez-Margalet V. Human leptin activates PI3K and MAPK pathways in human peripheral blood mononuclear cells: possible role of Sam68. Cell Immunol 2001; 212: 83-91
37. Steinberg GR, Kemp BE. Adiponectin: starving for attention. Cell Metab 2007; 6: 3-4
38. Cammisotto PG, Geĺinas Y, Deshaies Y, Bukowiecki L J. Regulation of leptin secretion from white adipocytes by insulin, glycolytic substrates, and amino acids. Am J Physiol Endocrinol Metab 2005; 289: E166-E171
39. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Com-mun 1999; 257: 79-83
40. Tsujimoto M, Yip YK, Vilcek J. Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci USA 1985; 82: 7626-7630
41. Samad F, Uysal KT, Wiesbrock SM et al. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-6907
42. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adiposespecific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289
43. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterisation of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803-812
44. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
45. Samad F, Uysal KT, Wiesbrock SM et al. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-6907
46. Xu H, Hotamisligil GS. Pathways utilized by tumor necrosis factor receptor 1 in adipocytes to suppress differentiation. FEBS Lett 2001; 506: 97-102
47. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999; 10:19-29
48. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97: 37-46
49. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipi-demia. Diabetes 1992; 2: 97-101
50. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301
51. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158